keyword
MENU ▼
Read by QxMD icon Read
search

neprilysin

keyword
https://www.readbyqxmd.com/read/29450561/cognitive-performance-of-patients-with-chronic-heart-failure-on-sacubitril-valsartan-a-retrospective-cohort-study
#1
R De Vecchis, C Ariano, G Di Biase, M Noutsias
BACKGROUND: Sacubitril, a neprilysin inhibitor in the combination molecule sacubitril/valsartan, slows down degradation of endogenous natriuretic peptides, thereby enhancing their beneficial cardiovascular effects. However, sacubitril might also promote neuronal dysfunction and cognitive impairment in patients with chronic heart failure (CHF) treated with sacubitril/valsartan, due to possible neprilysin inhibition at the level of Central Nervous System. METHODS: A retrospective cohort study was undertaken to detect the effects exerted by sacubitril/valsartan on cognitive function in CHF patients...
February 15, 2018: Herz
https://www.readbyqxmd.com/read/29432709/neprilysin-inhibition-and-endothelin-1-elevation-focus-on-the-kidney
#2
Lodi C W Roksnoer, Estrellita Uijl, René de Vries, Ingrid M Garrelds, A H Jan Danser
Increasing the degree of renin-angiotensin system (RAS) blockade by combining ≥2 RAS blockers marginally increases efficacy, but results in more side effects. Hence, interference with other systems is currently being investigated, like potentiation of natriuretic peptides with neprilysin inhibitors. However, the neprilysin inhibitor thiorphan was recently found to increase endothelin-1 when administered to TGR(mREN2)27 (Ren2) rats on top of RAS blockade. Here we investigated whether this effect is thiorphan-specific, by comparing the neprilysin inhibitors thiorphan and sacubitril, administered by osmotic minipumps at a low or high dose for 7 days, in Ren2 rats...
February 9, 2018: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29415801/bio-profiling-and-bio-prognostication-of-chronic-heart-failure-with-mid-range-ejection-fraction
#3
Pedro Moliner, Josep Lupón, Jaume Barallat, Marta de Antonio, Mar Domingo, Julio Núñez, Elisabet Zamora, Amparo Galán, Javier Santesmases, Cruz Pastor, Antoni Bayes-Genis
BACKGROUND: Recent ESC guidelines on heart failure (HF) have introduced a new phenotype based on left ventricular ejection fraction (LVEF), called the mid-range (HFmrEF). This phenotype falls between the classical reduced (HFrEF) and preserved (HFpEF) HF phenotypes. We aimed to characterize the HFmrEF biomarker profile and outcomes. METHODS: 1069 consecutive ambulatory patients were included in the study (age 66.2 ± 12.8 years); 800 with HFrEF (74.8%), 134 with HFmrEF (12...
January 31, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29407093/evolution-of-natriuretic-peptide-biomarkers-in-heart-failure-implications-for-clinical-care-and-clinical-trials
#4
Nicolas Vodovar, Alexandre Mebazaa, James L Januzzi, Gillian Murtagh, Wendy Gattis Stough, Kirkwood F Adams, Faiez Zannad
Natriuretic peptides (NPs) are recommended by international guidelines to exclude non-heart failure causes of acute dyspnea and to assess prognosis. NPs are commonly used as an entry criterion for clinical trials, to minimize enrollment of misdiagnosed patients, or to ensure enrollment of a sufficiently at-risk population. NP values used to select trial populations to date have been inconsistent across studies. Future trials should consider using standardized thresholds for NP levels, with protocol-specified adaptations appropriate for the specific study and patient population to account for factors that can influence the NP level...
March 1, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29383889/-effect-of-electroacupuncture-on-levels-of-%C3%AE-amyloid-and-neprilysin-proteins-in-the-cerebral-cortex-of-alzheimer-s-disease-mice-based-on-mutual-assistance-of-kidney-and-brain-theory
#5
Xu Wang, Yue Wang, Song Yu, Lu Ren
OBJECTIVE: To observe the effect of electroacupuncture (EA) on the levels of Aβ 1-40 and Aβ 1-42 and neprilysin (NEP) protein in the temporal cortex of SAMP 8 mice with Alzheimer's disease (AD), so as to explore its mechanism underlying improvement of AD based on the theory of "mutual assistance of kidney and brain" in traditional Chinese medicine. METHODS: Eighteen male SAMP 8 mice were randomly assigned to 3 groups: model, EA and medication (memantine, n=6/group), and 6 male homologous SAMR 1 mice were used as the normal control group...
January 25, 2018: Zhen Ci Yan Jiu, Acupuncture Research
https://www.readbyqxmd.com/read/29380564/in-situ-tissue-regeneration-of-renal-tissue-induced-by-collagen-hydrogel-injection
#6
Sang Jin Lee, Hung-Jen Wang, Tae-Hyoung Kim, Jin San Choi, Gauri Kulkarni, John D Jackson, Anthony Atala, James J Yoo
Host stem/progenitor cells can be mobilized and recruited to a target location using biomaterials, and these cells may be used for in situ tissue regeneration. The objective of this study was to investigate whether host biologic resources could be used to regenerate renal tissue in situ. Collagen hydrogel was injected into the kidneys of normal mice, and rat kidneys that had sustained ischemia/reperfusion injury. After injection, the kidneys of both animal models were examined up to 4 weeks for host tissue response...
February 2018: Stem Cells Translational Medicine
https://www.readbyqxmd.com/read/29378257/neprilysin-inhibition-what-we-know-and-what-we-don-t-know
#7
EDITORIAL
Peter Buttrick
No abstract text is available yet for this article.
January 26, 2018: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/29374807/the-sacubitril-valsartan-a-first-in-class-angiotensin-receptor-neprilysin-inhibitor-arni-potential-uses-in-hypertension-heart-failure-and-beyond
#8
REVIEW
Kazuomi Kario
PURPOSE OF REVIEW: Sacubitril/valsartan (LCZ696) is a first-in-class, novel-acting, angiotensin receptor neprilysin inhibitor (ARNI) that provides inhibition of neprilysin and the angiotensin (AT 1 ) receptor. A recent clinical trial PRARDIGM-HF demonstrated that this drug is superior to angiotensin-converting enzyme (ACE) inhibitors for improving the prognosis in the patients with heart failure, and this has resulted in the drug being included in clinical practice guidelines for the management of heart failure with reduced ejection fraction (EF)...
January 27, 2018: Current Cardiology Reports
https://www.readbyqxmd.com/read/29369824/was-the-enalapril-dose-too-low-in-the-paradigm-hf-trial
#9
Sabrina Bernardez-Pereira, Felix José Alvares Ramires, Rachel Figueiredo Tavares de Melo, Antonio Carlos Pereira-Barretto
Heart failure (HF) is a common clinical syndrome associated with significant morbidity and mortality, and there remains a clear need for innovative therapies that can modify disease progression. Sacubitril/valsartan (LCZ696) is a novel complex that combines simultaneous neprilysin inhibition and angiotensin II receptor blockade, that has demonstrated significant cardiovascular death or HF hospitalization reduction in the Prospective Comparison of Angiotensin Receptor/Neprilysin Inhibitor (ARNI) with Angiotensin-Converting Enzyme (ACE) Inhibitors to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial when compared to evidence-based doses of the gold-standard ACE inhibitor enalapril...
January 24, 2018: Cardiology in Review
https://www.readbyqxmd.com/read/29345425/eligibility-of-sacubitril-valsartan-in-a-real-world-heart-failure-population-a-community-based-single-centre-study
#10
Helena Norberg, Ellinor Bergdahl, Krister Lindmark
AIMS: This study aims to investigate the eligibility of the Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor (ARNI) with ACE inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) study to a real-world heart failure population. METHODS AND RESULTS: Medical records of all heart failure patients living within the catchment area of Umeå University Hospital were reviewed. This district consists of around 150 000 people...
January 18, 2018: ESC Heart Failure
https://www.readbyqxmd.com/read/29339171/dna-methylation-level-of-the-neprilysin-promoter-in-alzheimer-s-disease-brains
#11
Kenichi Nagata, Tatsuo Mano, Shigeo Murayama, Takaomi C Saido, Atsushi Iwata
Neprilysin (NEP), a membrane-bound metalloprotease, has been shown to play an essential role in the clearance of amyloid beta (Aβ) peptides. Previous studies have reported that NEP expression is downregulated in the normal aging brain as well as in the Alzheimer's disease (AD) brain, providing evidence that the downregulation of NEP expression contributes to the age-dependent deposition of Aβ-containing plaques, a pathological hallmark of AD. However, the mechanisms underlying the downregulation remain unclear...
January 12, 2018: Neuroscience Letters
https://www.readbyqxmd.com/read/29330223/the-anti-oxidant-xanthorrhizol-prevents-amyloid-%C3%AE-induced-oxidative-modification-and-inactivation-of-neprilysin
#12
Chol Seung Lim, Jung-Soo Han
Activity of neprilysin (NEP), the major protease which cleaves β-amyloid (Aβ), is reportedly reduced in the brains of patients with Alzheimer's disease (AD). Accumulation of Aβ generates reactive oxygen species (ROS) such as 4-hydroxy nonenal (HNE), and then reduces activities of Aβ-degrading enzymes including NEP. Xanthorrhizol (Xan), a natural sesquiterpenoid, has been reported to possess anti-oxidant and anti-inflammatory properties. The present study examined the effects of Xan on HNE- or oligomeric Aβ42-induced oxidative modification of NEP protein...
January 12, 2018: Bioscience Reports
https://www.readbyqxmd.com/read/29325796/lcz696-sacubitril-valsartan-an-angiotensin-receptor-neprilysin-inhibitor-attenuates-cardiac-hypertrophy-fibrosis-and-vasculopathy-in-a-rat-model-of-chronic-kidney-disease
#13
Yasunori Suematsu, Wanghui Jing, Ane Nunes, Moti L Kashyap, Mahyar Khazaeli, Nosratola D Vaziri, Hamid Moradi
BACKGROUND: Chronic kidney disease (CKD) is associated with cardiac hypertrophy, fibrosis and increased risk of cardiovascular mortality. LCZ696 (Sacubitril/valsartan) is a promising agent which has shown significant potential in treatment of heart failure. We hypothesized that LCZ696 is more effective than valsartan alone in treatment of cardiovascular abnormalities associated with experimental CKD. METHODS AND RESULTS: Male Sprague Dawley rats underwent 5/6 nephrectomy and were subsequently randomized to no treatment (CKD), 30 mg/kg valsartan (VAL), or 60 mg/kg LCZ696 (LCZ)...
January 8, 2018: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/29323711/hiv-1-increases-extracellular-amyloid-beta-levels-through-neprilysin-regulation-in-primary-cultures-of-human-astrocytes
#14
Marta Martínez-Bonet, M Ángeles Muñoz-Fernández, Susana Álvarez
Since the success of combined antiretroviral therapy, HIV-1-infected individuals are now living much longer. This increased life expectancy is accompanied by a higher prevalence of HIV-1 associated neurocognitive disorders. Rising too is the incidence in these patients of pathological hallmarks of Alzheimer's disease such as increased deposition of amyloid beta protein (Aβ). Although neurons are major sources of Aβ in the brain, astrocytes are the most numerous glial cells, therefore, even a small level of astrocytic Aβ metabolism could make a significant contribution to brain pathology...
January 11, 2018: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29318651/effect-of-the-angiotensin-receptor-neprilysin-inhibitor-sacubitril-valsartan-on-pharmacokinetics-and-pharmacodynamics-of-a-single-dose-of-furosemide
#15
Surya Ayalasomayajula, Uwe Schuehly, Parasar Pal, Fabian Chen, Wei Zhou, Gangadhar Sunkara, Thomas H Langenickel
AIMS: Sacubitril/valsartan is indicated for the treatment of heart failure and reduced ejection fraction (HFrEF). Furosemide, a loop diuretic commonly used for the treatment of HFrEF, may be co-administrated with sacubitril/valsartan in clinical practice. The effect of sacubitril/valsartan on pharmacokinetics and pharmacodynamics of furosemide was evaluated in this open label, two- period, single-sequence study in healthy subjects (N=28). METHODS: All subjects received 40 mg oral single dose furosemide during period 1 followed by washout of 2 days...
January 9, 2018: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29305970/does-neprilysin-inhibition-potentiate-or-minimize-the-adverse-effects-of-glucagon-like-peptide-1-receptor-agonists-in-chronic-heart-failure
#16
EDITORIAL
Milton Packer
No abstract text is available yet for this article.
January 3, 2018: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/29300199/recent-advances-in-heart-failure
#17
Mahwash Kassi, Bashar Hannawi, Barry Trachtenberg
PURPOSE OF REVIEW: Acute heart failure continues to be a challenge as there is limited benefit of numerous agents that have been tested. Cardiac resynchronization therapy remains standard of care, yet timing and need for implantable cardiac defibrillator has been brought into question with the recent randomized trials. Several recent advances have been made towards management of heart failure both in drug and device therapy. The purpose of this review is to provide an update on the most important recent studies on heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF)...
March 2018: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/29286056/sacubitril-and-valsartan-fixed-combination-to-reduce-heart-failure-events-in-post-acute-myocardial-infarction-patients
#18
M Zaid Iskandar, C C Lang
Heart failure is a term used to define a constellation of symptoms and signs that are commonly attributed to the inability of the heart to produce a cardiac output that meets the demands of the body. It remains a deadly disease, affecting between 1-2% of the population, and is more common in the elderly, with around 6-10% of patients over 65 suffering from the condition. Sacubitril/valsartan (LCZ-696) is a combined neprilysin inhibitor and angiotensin AT1 receptor blocker approved in recent years for the treatment of chronic heart failure with reduced ejection fraction...
October 2017: Drugs of Today
https://www.readbyqxmd.com/read/29244074/the-heart-regulates-the-endocrine-response-to-heart-failure-cardiac-contribution-to-circulating-neprilysin
#19
Mattia Arrigo, Nicolas Vodovar, Hélène Nougué, Malha Sadoune, Chris J Pemberton, Pamela Ballan, Pierre-Olivier Ludes, Nicolas Gendron, Alain Carpentier, Bernard Cholley, Philippe Bizouarn, Alain Cohen-Solal, Jagmeet P Singh, Jackie Szymonifka, Christian Latremouille, Jane-Lise Samuel, Jean-Marie Launay, Julien Pottecher, A Mark Richards, Quynh A Truong, David M Smadja, Alexandre Mebazaa
Aims: Heart failure (HF) is accompanied by major neuroendocrine changes including the activation of the natriuretic peptide (NP) pathway. Using the unique model of patients undergoing implantation of the CARMAT total artificial heart and investigating regional differences in soluble neprilysin (sNEP) in patients with reduced or preserved systolic function, we studied the regulation of the NP pathway in HF. Methods and results: Venous blood samples from two patients undergoing replacement of the failing ventricles with a total artificial heart were collected before implantation and weekly thereafter until post-operative week 6...
December 13, 2017: European Heart Journal
https://www.readbyqxmd.com/read/29241885/cost-effectiveness-of-the-angiotensin-receptor-neprilysin-inhibitor-sacubitril-valsartan-for-patients-with-chronic-heart-failure-and-reduced-ejection-fraction-in-the-netherlands-a-country-adaptation-analysis-under-the-former-and-current-dutch-pharmacoeconomic
#20
COMPARATIVE STUDY
Isaac Corro Ramos, Matthijs M Versteegh, Rudolf A de Boer, Jolanda M A Koenders, Gerard C M Linssen, Joan G Meeder, Maureen P M H Rutten-van Mölken
OBJECTIVES: To describe the adaptation of a global health economic model to determine whether treatment with the angiotensin receptor neprilysin inhibitor LCZ696 is cost effective compared with the angiotensin-converting enzyme inhibitor enalapril in adult patients with chronic heart failure with reduced left ventricular ejection fraction in the Netherlands; and to explore the effect of performing the cost-effectiveness analyses according to the new pharmacoeconomic Dutch guidelines (updated during the submission process of LCZ696), which require a value-of-information analysis and the inclusion of indirect medical costs of life-years gained...
December 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
67252
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"